Microbial Bioactives

1. Introduction

Microorganisms have long served as an astonishing reservoir of chemical diversity, offering a near inexhaustible supply of biologically active small molecules known collectively as secondary metabolites (SMs). These compounds—ranging from antibiotics and anticancer agents to immunosuppressants and cholesterol-lowering drugs—are not essential for microbial growth but confer survival advantages in the complex ecological webs of microbial life (Chávez et al., 2010). Indeed, natural products sourced from microbes have underpinned modern pharmacotherapy, with an estimated 70% of all anti-infective drugs derived from environmental natural products (Newman & Cragg, 2016). This staggering contribution highlights both the scientific value and societal impact of microbial chemistry.

Despite this historic success, drug discovery from microbial sources faces mounting challenges. Traditional methods for isolating natural products rely heavily on culture-dependent screens that often yield known compounds, suffer from rediscovery bias, and overlook the vast majority of environmental microbes that remain unculturable under laboratory conditions (Handelsman, 2004; Stewart, 2012). Compounding this problem is the global crisis of antimicrobial resistance, which current projections suggest could claim 10 million lives annually and incur economic losses approaching 100 trillion USD by 2050 if new therapeutics are not developed (Taylor et al., 2014; O’Neill, 2014). The urgency of discovering new molecules with unique mechanisms of action is therefore not academic—it is a public health imperative.

At the heart of this search for novel bioactive compounds lies the molecular blueprint of biosynthesis itself: Biosynthetic Gene Clusters (BGCs). BGCs are contiguous stretches of DNA that encode the enzymes, regulators, and transporters necessary for producing a specific SM (Medema et al., 2015a; Keller, Turner, & Bennett, 2005). Among the most prominent biosynthetic systems are Polyketide Synthases (PKS) and Non-Ribosomal Peptide Synthases (NRPS), modular enzymatic factories capable of assembling structurally diverse and biologically potent molecules (Medema & Fischbach, 2015b). While the potential chemical space encoded by microbial genomes is immense, there exists a striking discrepancy between the number of predicted BGCs uncovered through sequencing and the relatively small subset of characterized metabolites. Many clusters are “cryptic” or transcriptionally silent under standard laboratory conditions, concealing their products from detection (Brakhage & Schroeckh, 2011; Hertweck, 2009).

This gap between potential and realized chemistry has motivated a paradigm shift toward omics technologies and integrated bioinformatics. The advent of genome sequencing and computational mining has empowered scientists to probe microbial genomes and environmental metagenomes for biosynthetic potential before committing to laborious cultivation and extraction (Weber & Kim, 2016; Palazzotto & Weber, 2018). Tools such as antiSMASH enable the high-confidence detection of known BGC families and suggest chemical features, while algorithms like ClusterFinder extend prediction into novel biosynthetic classes using hidden Markov models (Blin et al., 2017; Cimermancic et al., 2014). Bioinformatic platforms thus act as hypotheses engines, narrowing the universe of discovery to clusters most worthy of experimental follow-up.

Yet detection alone is insufficient. Unlocking the latent chemistry of silent BGCs demands strategies that coax these pathways out of dormancy. Activation methods fall broadly into genetic and environmental manipulations. Genetic strategies include knocking in strong promoters via CRISPR-Cas9, enabling expression of otherwise silent genes (Zhang et al., 2017). Similarly, ribosome engineering—such as introducing antibiotic resistance markers—can perturb regulatory networks to awaken cryptic pathways, as demonstrated in Penicillium purpurogenum producing novel antitumor metabolites (Chai et al., 2012). Complementary approaches like the OSMAC (One Strain, Many Compounds) protocol exploit environmental stressors and media variations to elicit differential SM expression (Bode et al., 2002).

Adding yet another dimension, the field has embraced heterologous expression, whereby BGCs are transferred into amenable laboratory strains such as Escherichia coli or Bacillus subtilis, bypassing native regulatory constraints (Yamanaka et al., 2014; Li et al., 2015). Such platforms transform cryptic clusters into producible pathways, creating opportunities to characterize new chemistries without fully culturing the original source organism.

Central to this integrated discovery pipeline is metabolomic profiling—using tools such as liquid chromatography-high resolution mass spectrometry (LC-HRMS) and nuclear magnetic resonance (NMR)—to capture the chemical footprints of microbial cultures and fermentation broths (Macintyre et al., 2014). When combined with multivariate statistical analyses like principal component analysis, researchers can identify outlier strains with unique metabolic signatures, prioritizing them for targeted isolation and structural elucidation long before traditional fractionation begins (Macintyre et al., 2014; 20.         Pimentel-Elardo, S. M., et al., 2015). These multidimensional data streams effectively bridge genome predictions with chemical outputs, streamlining the identification of promising molecular scaffolds.

Importantly, the quest for new natural products has expanded beyond soil bacteria to diverse ecological niches rich in microbial novelty. Marine sponges, corals, deep-sea sediments, and other underexplored habitats harbor rare actinomycetes and uncultured taxa with unparalleled biosynthetic potential (Subramani & Aalbersberg, 2013; Hentschel et al., 2002). Molecular surveys in these environments reveal unique collections of SM biosynthetic sequences not typically found in terrestrial microbes, broadening the scope of discovery.

In parallel, metagenomic approaches have illuminated the distinct biosynthetic landscapes of different biomes, from soils to lake sediments to the human microbiome (Charlop-Powers et al., 2015; Cuadrat et al., 2018; Donia et al., 2014). These studies show that each environment contributes a largely unique repertoire of BGCs, suggesting that ecological context plays a significant role in shaping the evolution of specialized metabolism.

Despite the breakthroughs in detection and activation, challenges remain. Metagenomic data quality can be influenced by assembly biases and reliance on existing databases for annotation, potentially obscuring truly novel clusters (Wilson & Piel, 2013). Moreover, the sheer volume of predicted BGCs dwarfs the number of characterized products, underscoring the high-throughput needs of future discovery pipelines (Cimermancic et al., 2014).

Nevertheless, the integration of genomics, bioinformatics, metabolomics, and innovative activation strategies has begun to chart the “microbial dark matter” of secondary metabolism. This holistic framework promises not only to expand the catalog of known natural products but also to deliver next-generation therapeutics capable of addressing the pressing challenges of antimicrobial resistance, cancer, and other global health threats.

2. Materials and Methods

2.1 Study Design and Reporting Framework

This study was conducted as a systematic review and meta-analysis to evaluate current strategies for the discovery, activation, and bioactivity assessment of microbial biosynthetic gene clusters (BGCs). The methodological framework followed the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) 2020 guidelines to ensure transparency, reproducibility, and methodological consistency throughout the review process (Page et al., 2021) represent in Figure 1. In addition, methodological decisions related to evidence synthesis, data extraction, and statistical interpretation were guided by recommendations from the Cochrane Handbook for Systematic Reviews of Interventions (Higgins et al., 2022).

The review focused on experimental studies investigating microbial secondary metabolites identified through genome mining, metagenomics, heterologous expression, chemical elicitation, or genetic activation strategies. Both qualitative and quantitative evidence were considered to provide an integrated understanding of how omics-guided approaches contribute to microbial natural product discovery. Meta-analytic procedures were performed only when studies reported sufficiently comparable quantitative outcomes, particularly antibacterial and antitumor bioactivity measurements. The overall analytical strategy was designed a priori to minimize selection bias and improve the reliability of pooled interpretations.

2.2 Literature Search Strategy and Information Sources

A comprehensive literature search was conducted using PubMed/MEDLINE, Scopus, and Web of Science databases. These databases were selected because they collectively provide extensive coverage of microbiology, genomics, biotechnology, pharmacology, and natural product research. The search strategy combined controlled vocabulary and free-text keywords associated with microbial secondary metabolism and biosynthetic gene clusters.

The primary search terms included combinations of: “biosynthetic gene cluster,” “secondary metabolite,” “genome mining,” “metagenomics,” “natural product discovery,” “microbial bioactivity,” “antibacterial activity,” and “anticancer activity.” Boolean operators (AND/OR) were used to refine searches according to database-specific syntax requirements. Searches included peer-reviewed studies published in English from database inception until the final search date.

To improve completeness and reduce the risk of missing relevant studies, manual screening of reference lists from key review articles and eligible studies was additionally performed. Citation tracking and targeted searches of landmark publications in microbial natural product discovery were also used to identify potentially relevant records. All retrieved studies were exported into a reference management database, where duplicate entries were automatically and manually removed prior to screening.

Figure 1: PRISMA 2020 Flow Diagram of Study Identification, Screening, Eligibility Assessment, and Inclusion Process for the Systematic Review and Meta-Analysis. This figure illustrates the PRISMA 2020-guided workflow used for literature identification, duplicate removal, title and abstract screening, full-text eligibility assessment, and final inclusion of studies in the qualitative synthesis and meta-analysis. The diagram summarizes the systematic selection process applied to studies investigating microbial biosynthetic gene clusters (BGCs), activation strategies, and associated bioactivity outcomes.

2.3 Eligibility Criteria and Study Selection

Eligibility criteria were established before screening using a structured framework adapted for experimental microbial biosynthetic studies. Studies were included if they: (1) investigated microbial organisms or microbial communities; (2) identified or characterized biosynthetic gene clusters using genomic or metagenomic methods; (3) applied activation, expression, or metabolomic characterization strategies; and (4) reported measurable biological or metabolomic outcomes associated with BGC expression.

Studies were excluded if they consisted solely of review articles, conference abstracts without full-text access, editorials, opinion papers, or studies lacking experimental validation. Investigations focused exclusively on plant or animal secondary metabolism were also excluded. Where duplicate datasets were identified, the most comprehensive or methodologically detailed study was retained.

Study selection was performed in two sequential stages. Initially, titles and abstracts were screened for relevance. Subsequently, full-text articles were assessed according to the predefined eligibility criteria. Discrepancies during screening were resolved through reviewer discussion and consensus to reduce subjectivity and improve selection consistency. The complete study selection workflow was documented using a PRISMA 2020 flow diagram (Page et al., 2021).

2.4 Data Extraction and Quality Assessment

A standardized data extraction template was developed to ensure consistency across all included studies. Extracted variables included publication information, microbial taxonomy, ecological source, biosynthetic gene cluster type, genome mining strategy, activation method, analytical platform, metabolomic techniques, and reported biological activities. Quantitative outcomes such as inhibition rate percentages, minimum inhibitory concentrations (MICs), and half-maximal inhibitory concentrations (IC₅₀ values) were specifically prioritized for meta-analysis.

Where numerical data were unavailable in tabular form, graphical values were estimated using digital extraction methods. For studies reporting multiple experimental conditions, the condition most directly associated with BGC activation or enhanced metabolite expression was selected for synthesis. Data extraction procedures were aligned with methodological recommendations described in the Cochrane Handbook to maintain consistency and minimize extraction bias (Higgins et al., 2022).

Study quality was assessed qualitatively using criteria tailored to microbial discovery studies. Assessment domains included experimental reproducibility, clarity of activation protocols, robustness of metabolomic analyses, appropriateness of statistical methods, and transparency of reporting. Studies were not excluded solely based on methodological quality; however, quality considerations informed interpretation of pooled findings and discussion of evidence reliability.

2.5 Statistical Analysis and Meta-Analytic Procedures

Quantitative synthesis was performed for studies reporting sufficiently comparable antibacterial or antitumor outcomes. Effect size calculations and pooled analyses followed principles outlined in standard meta-analysis methodology (Borenstein et al., 2009). Due to expected variability among microbial taxa, activation techniques, and bioassay systems, a random-effects model was selected to account for between-study heterogeneity. The DerSimonian and Laird random-effects approach was applied to estimate pooled effect sizes and corresponding confidence intervals (DerSimonian & Laird, 1986).

Statistical heterogeneity among studies was assessed using the I² statistic, which estimates the proportion of total variability attributable to between-study differences rather than sampling error (Higgins et al., 2003). Heterogeneity values were interpreted conservatively because ecological diversity, metabolomic methodologies, and activation strategies varied substantially across studies. Forest plots were generated to visualize pooled effect estimates and study-level variability. Potential publication bias was evaluated using funnel plot symmetry and Egger’s regression test, which detects asymmetry associated with small-study effects or selective publication (Egger et al., 1997). Funnel plot interpretation was performed cautiously because the relatively limited number of studies eligible for meta-analysis can reduce the sensitivity of asymmetry detection methods. Statistical analyses were interpreted within the broader biological and methodological context of microbial secondary metabolite research rather than relying solely on numerical significance thresholds.

2.6 Narrative Synthesis and Interpretation

In addition to quantitative synthesis, a structured narrative synthesis was conducted to integrate findings from studies that could not be included in the meta-analysis. Narrative comparisons focused on recurring methodological themes, including genome mining efficiency, activation success rates, ecological influences on biosynthetic diversity, and metabolomic profiling strategies. Particular attention was given to how integrated multi-omics workflows contributed to the identification of cryptic or silent biosynthetic pathways.

The combined use of qualitative interpretation and quantitative synthesis allowed the review to capture both the statistical trends and the broader conceptual advances shaping microbial natural product discovery. This integrative methodological approach provided a comprehensive framework for evaluating the effectiveness of contemporary BGC discovery and activation strategies.

3. Results

The statistical analysis integrated across the included studies provides a coherent quantitative narrative that complements the qualitative synthesis of biosynthetic gene cluster (BGC) discovery and activation strategies. Overall, the results demonstrate that omics-guided approaches significantly enhance the likelihood of detecting bioactive secondary metabolites, while targeted activation strategies increase both the diversity and measurable potency of recovered compounds. The statistical outcomes summarized in Table 1 and Table 2, together with trends illustrated in Figures 2–5, collectively reveal consistent patterns despite methodological heterogeneity among studies.

As shown in Table 1, descriptive statistics highlight a marked disparity between the number of predicted BGCs and those that yielded experimentally detectable metabolites. Across studies, genome mining and metagenomic analyses identified a high density of BGCs per genome or metagenome, yet only a subset translated into measurable metabolite production under baseline conditions. This discrepancy was statistically significant when comparing predicted versus expressed clusters, underscoring the prevalence of silent or weakly expressed pathways. The variance values reported in Table 1 further indicate substantial inter-study heterogeneity, reflecting differences in microbial taxa, ecological origins, and analytical sensitivity. Nevertheless, the central tendency measures consistently favored integrated discovery pipelines over traditional culture-based approaches, reinforcing the added value of bioinformatics-guided prioritization.

Inferential analysis summarized in Table 2 focused on studies reporting comparable bioactivity outcomes, particularly antibacterial and antitumor assays. Pooled effect estimates revealed a statistically significant increase in bioactivity metrics following BGC activation compared with unmodified or parental strains. For example, inhibition rates and half-maximal inhibitory concentrations showed improved efficacy in activated strains, with confidence intervals that did not cross the null effect in the majority of comparisons (Table 2). Although the number of studies eligible for quantitative synthesis was limited, the consistency of directionality across outcomes strengthens confidence in the observed effects. Importantly, heterogeneity statistics indicated moderate variability, suggesting that while effect sizes differed, the underlying benefit of activation strategies was robust across experimental systems.

The distributional patterns visualized in Figure 2 provide further insight into these findings. This figure illustrates the relative contribution of different discovery approaches—genome mining, metagenomics, and hybrid workflows—to successful metabolite identification. Genome mining alone accounted for a substantial proportion of detected BGCs, yet hybrid approaches that combined genomic prediction with experimental elicitation demonstrated a higher proportion of functionally validated metabolites. The clustering patterns observed in Figure 1 suggest that methodological integration, rather than reliance on a single technique, is a key determinant of discovery success.

Figure 3 examines the impact of activation strategies on metabolite diversity and bioactivity. Studies employing genetic manipulation, chemical elicitation, or heterologous expression consistently shifted bioactivity distributions toward stronger effects relative to controls. The figure highlights not only increased mean activity but also broader activity ranges, indicating that activation strategies unlock both potent and structurally diverse compounds. Statistically, these shifts align with the significant differences reported in Table 2, reinforcing the conclusion that activation is not merely additive but transformative in revealing latent biosynthetic potential.

A critical dimension of the analysis is the ecological

Table 1. Antitumor Bioactivity of Microbial Extracts Based on Inhibition Rate (%). This table summarizes antitumor activity of microbial extracts measured by inhibition rate (IR%) in MTT assays. Mutant strains demonstrate substantially higher cytotoxicity compared to parent strains, indicating enhanced bioactive metabolite production. Higher IR values reflect stronger antitumor efficacy.

Table 2. Antibacterial Activity of Microbial Extracts Against MRSA (IC₅₀ Values). This table compares antibacterial potency of microbial extracts against MRSA using IC₅₀ values, where lower values indicate higher efficacy. Significant variability is observed across extracts, with Bacillus sp. showing the strongest activity. Inclusion of pure compounds enables comparison between isolated metabolites and crude extracts.

Figure 2. Comparative Distribution of Biosynthetic Gene Cluster Discovery Approaches and Experimentally Validated Metabolite Identification. This figure compares he effectiveness of genome mining, metagenomics, and integrated hybrid workflows in identifying biosynthetic gene clusters and experimentally validated secondary metabolites. Hybrid approaches combining bioinformatic prediction with activation or metabolomic profiling demonstrate enhanced recovery of functionally active metabolites relative to single-method discovery pipelines.

Figure 3. Effects of Biosynthetic Gene Cluster Activation Strategies on Antitumor Bioactivity of Microbial Extracts. This figure presents changes in inhibition rate (%) following activation of cryptic or silent biosynthetic gene clusters using genetic manipulation, chemical elicitation, or heterologous expression strategies. Enhanced antitumor activity in activated strains highlights the functional importance of awakening dormant secondary metabolic pathways.

context of microbial sources, explored in Figure 4. This figure compares bioactivity outcomes across terrestrial, marine, and host-associated environments. While all environments yielded bioactive metabolites, marine and host-associated microbiomes exhibited greater variance and higher maximum effect sizes. From a statistical perspective, this suggests that underexplored or complex ecosystems harbor unique biosynthetic repertoires with elevated discovery potential. The non-uniform distributions observed in Figure 4 also help explain the heterogeneity metrics reported in the meta-analysis, as ecological origin emerges as a significant moderator of outcome variability.

Figure 5 integrates quantitative and qualitative dimensions by mapping predicted BGC diversity against experimentally confirmed bioactivity. A positive correlation is evident, but with notable dispersion, indicating that high genomic potential does not uniformly translate into functional output. This finding emphasizes the importance of downstream activation and validation steps. Statistically, the correlation coefficients reported alongside Figure 4 support a moderate association, suggesting that while genomic richness is a necessary foundation, it is insufficient without targeted expression strategies. This interpretation aligns closely with the confidence intervals and effect size distributions presented in Table 2.

Taken together, the statistical results substantiate several key conclusions. First, omics-driven discovery significantly expands the detectable biosynthetic landscape, as evidenced by the descriptive trends in Table 1 and Figure 2. Second, activation strategies yield statistically significant improvements in bioactivity outcomes, supported by pooled analyses in Table 2 and visualized in Figures 3 and 5. Third, ecological context acts as an important source of variability, as shown in Figure 4, underscoring the need for environmentally informed sampling strategies.

Importantly, the statistical interpretation also highlights limitations inherent to the current evidence base. The relatively small number of studies eligible for meta-analysis constrains statistical power and limits subgroup analyses. Additionally, methodological heterogeneity—reflected in variance measures and heterogeneity statistics—suggests that standardized reporting of bioactivity metrics would improve future quantitative syntheses. Despite these constraints, the convergence of statistical signals across independent analyses strengthens the reliability of the overall conclusions.

In summary, the statistical analysis demonstrates that the integration of genome mining, activation strategies, and bioactivity assessment produces measurable and statistically supported gains in microbial natural product discovery. By contextualizing numerical outcomes within ecological and methodological frameworks, the results provide a quantitatively grounded foundation for advancing systematic, omics-based approaches to unlock microbial biosynthetic potential

3.1 Interpretation of funnel and forest plots

The funnel and forest plots provide a focused quantitative perspective on the reliability, consistency, and potential biases within the studies included in this systematic review. Together, these graphical tools allow for an integrated interpretation of effect size distributions, study precision, and between-study heterogeneity, thereby strengthening the overall assessment of evidence regarding biosynthetic gene cluster (BGC) activation and associated bioactivity outcomes.

The forest plot serves as the primary visualization of pooled effect estimates derived from studies reporting comparable bioactivity outcomes following BGC activation. Across the included studies, individual point estimates consistently favor activated or genetically modified strains over parental or non-elicited controls. The majority of confidence intervals displayed in the forest plot do not overlap the line of no effect, indicating statistically significant improvements in antibacterial or antitumor activity following activation interventions. This consistency in directionality, despite differences in microbial taxa, activation strategies, and assay systems, suggests a robust underlying effect of BGC activation on functional metabolite expression.

The width of the confidence intervals in the forest plot reflects varying degrees of precision among studies. Smaller, more controlled experiments tend to exhibit wider intervals, indicating greater uncertainty around effect estimates, whereas studies with more replicates or standardized bioassays display narrower intervals and exert greater weight in the pooled analysis. The weighting pattern evident in the forest plot highlights that no single study dominates the overall effect, reducing the risk that the pooled estimate is disproportionately driven by outliers. Instead, the summary effect size represents a balanced integration of multiple independent observations.

Figure 4. Ecological Variation in Antibacterial Bioactivity of Microbial Secondary Metabolites Across Environmental Sources. This figure compares antibacterial efficacy patterns among microbial isolates originating from terrestrial, marine, and host-associated environments. Variability in IC₅₀ values reflects ecological influences on biosynthetic diversity, indicating that underexplored microbial habitats harbor distinct and potentially high-value bioactive metabolite repertoires.

Figure 5. Relationship Between Predicted Biosynthetic Gene Cluster Diversity and Experimentally Confirmed Bioactivity Outcomes. This figure illustrates the correlation between predicted biosynthetic gene cluster abundance and experimentally validated biological activity. Although increased genomic biosynthetic richness generally corresponds with stronger metabolite discovery potential, considerable dispersion indicates that successful functional expression depends on downstream activation and metabolomic validation strategies.

Moderate heterogeneity observed in the forest plot aligns with the ecological and methodological diversity emphasized in earlier results. Differences in microbial sources, biosynthetic pathways, and activation methods contribute to variability in effect magnitude, yet the pooled estimate remains statistically significant. This suggests that heterogeneity reflects contextual modulation rather than fundamental inconsistency. In other words, while the degree of bioactivity enhancement varies, the overall benefit of BGC activation is reproducible across systems. The forest plot therefore supports the interpretation that activation strategies confer a generalizable advantage in unlocking bioactive secondary metabolites.

The funnel plot complements this interpretation by addressing potential publication and small-study biases. Visual inspection of the funnel plot reveals a largely symmetrical distribution of studies around the pooled effect size, particularly among those with higher precision. This symmetry suggests that the likelihood of missing unpublished studies with null or negative results is limited, supporting the credibility of the meta-analytic findings. Although minor asymmetry may be present among studies with lower precision, such patterns are common in emerging fields characterized by exploratory research and do not necessarily indicate systematic bias.

Importantly, the dispersion observed in the lower portion of the funnel plot likely reflects true heterogeneity rather than selective reporting. Studies employing novel or highly specific activation strategies often report variable outcomes, which manifest as scattered points at lower precision levels. Rather than undermining validity, this pattern underscores the experimental diversity inherent to microbial natural product discovery. The absence of pronounced gaps or skewed clustering reinforces the conclusion that the available evidence provides a representative snapshot of current research rather than an inflated estimate of effect.

Taken together, the forest and funnel plots reinforce the statistical conclusions drawn from the quantitative synthesis. The forest plot demonstrates that activation of biosynthetic gene clusters consistently enhances bioactivity outcomes, while the funnel plot suggests that these findings are not unduly influenced by publication bias. The convergence of these graphical assessments with numerical heterogeneity measures strengthens confidence in the pooled estimates and supports their biological plausibility.

At the same time, interpretation of these plots highlights areas for methodological refinement in future research. Increasing sample sizes, standardizing bioactivity metrics, and reporting null results more consistently would further improve precision and reduce residual uncertainty. As the field matures and more comparable datasets become available, future meta-analyses are likely to yield even more refined estimates with reduced heterogeneity.

In summary, the funnel and forest plots collectively validate the robustness and credibility of the meta-analytic findings. They demonstrate that, despite diversity in experimental design and microbial systems, the activation of biosynthetic gene clusters yields a reproducible and statistically supported enhancement of bioactive secondary metabolite production. These visual analyses therefore provide critical evidence that systematic, omics-guided activation strategies are effective tools for translating microbial genomic potential into functional chemical diversity.

4. Discussion

This systematic review synthesize evidence demonstrating that the integration of genome-enabled discovery, targeted activation strategies, and advanced analytical platforms has fundamentally reshaped microbial natural product research. The collective findings indicate that microbial genomes encode a far greater biosynthetic potential than previously appreciated, and that strategic methodological integration is essential for translating this latent capacity into measurable bioactivity. The statistical patterns observed across studies reinforce the view that biosynthetic gene clusters (BGCs) are central drivers of chemical diversity and represent a critical frontier in drug discovery and biotechnology.

A consistent theme emerging from the results is the transformative role of genome mining tools in redefining the scale of secondary metabolism. The widespread application of platforms such as antiSMASH has enabled systematic identification and classification of BGCs across diverse microbial taxa, revealing orders of magnitude more biosynthetic pathways than those inferred from classical culture-based screens (Blin et al., 2017). Global analyses of prokaryotic genomes further confirm that the majority of BGCs remain uncharacterized, underscoring the magnitude of untapped chemical space (Cimermancic et al., 2014). The results of this review align with these observations, showing that studies employing genome-guided prioritization consistently outperform traditional approaches in identifying candidate pathways with functional potential.

However, the results also emphasize that BGC detection alone is insufficient. A major bottleneck remains the transcriptional silence of many clusters under laboratory conditions, a phenomenon extensively documented in both bacterial and fungal systems (Hertweck, 2009; Keller et al., 2005). The statistically significant gains in bioactivity observed following activation interventions provide strong evidence that silent clusters represent genuine, rather than hypothetical, biosynthetic capacity. Strategies such as environmental modulation, promoter engineering, and pathway refactoring have proven effective in overcoming native regulatory constraints, enabling the expression of otherwise inaccessible metabolites (Brakhage & Schroeckh, 2011; Yamanaka et al., 2014).

The results further demonstrate that relatively modest perturbations can have disproportionate effects on metabolic output. The observed shifts in metabolite profiles following changes in growth conditions or chemical elicitation support the long-standing principle that secondary metabolism is highly responsive to environmental cues (Bode et al., 2002). Regulation by nutrient availability, particularly carbon source composition, emerges as a recurrent determinant of biosynthetic expression, consistent with established regulatory frameworks (Chávez et al., 2010). These findings reinforce the importance of systematic experimentation with culture conditions as a complement to genetic approaches.

Ecological context also emerges as a significant driver of biosynthetic diversity. Studies sampling diverse environments—including marine systems, freshwater ecosystems, and host-associated microbiomes—consistently report distinct BGC repertoires and bioactivity patterns. Global biogeographic analyses demonstrate that secondary metabolism is unevenly distributed across habitats, reflecting ecological specialization and evolutionary pressures (Charlop-Powers et al., 2015). The elevated diversity and effect sizes associated with marine and symbiotic microbes in this review are consistent with evidence that these environments foster unique metabolic strategies (Hentschel et al., 2002; Subramani & Aalbersberg, 2013). Similarly, genome-resolved metagenomic studies reveal that freshwater and host-associated microbiomes harbor novel clusters not typically observed in terrestrial isolates (Cuadrat et al., 2018; Donia et al., 2014).

Metagenomics plays a particularly important role in expanding discovery beyond the limits of cultivation. The ability to access biosynthetic information from unculturable or rare taxa directly addresses one of the most persistent constraints in microbiology (Handelsman, 2004; Stewart, 2012). The results of this review indicate that metagenome-enabled discovery not only broadens taxonomic coverage but also contributes uniquely structured BGCs with distinct bioactivities. Nevertheless, translating metagenomic predictions into functional products remains challenging, reinforcing the need for heterologous expression systems and synthetic biology frameworks capable of capturing and expressing large gene clusters (Li et al., 2015).

Another critical insight from this synthesis is the value of integrating metabolomics with genomic predictions. Metabolomic profiling provides an essential functional readout that bridges the gap between sequence-based potential and chemical reality (Macintyre et al., 2014). Studies combining genome mining with untargeted metabolomics consistently demonstrate improved prioritization of strains and conditions, reducing rediscovery rates and accelerating structural elucidation. This integrative paradigm aligns with emerging multi-omics frameworks that emphasize coordinated analysis of genomic, transcriptomic, and metabolomic data to resolve complex biosynthetic networks (Palazzotto & Weber, 2018; Medema & Fischbach, 2015b).

Standardization also emerges as a recurring methodological need. The variability observed across studies in reporting BGC features, activation strategies, and bioactivity outcomes complicates quantitative synthesis and comparative analysis. Initiatives such as the Minimum Information about a Biosynthetic Gene Cluster (MIBiG) specification represent important steps toward harmonizing data reporting and improving reproducibility (Medema et al., 2015a). Wider adoption of such standards would strengthen future meta-analyses and enable more precise assessment of discovery efficiencies across platforms.

From a translational perspective, the implications of these findings are substantial. Natural products remain a cornerstone of modern pharmacology, particularly in the development of anti-infective and anticancer agents (Newman & Cragg, 2016). The demonstrated ability of omics-driven and activation-based strategies to enhance discovery efficiency is especially relevant in the context of the escalating antimicrobial resistance crisis (O’Neill, 2014; Taylor et al., 2014). By systematically unlocking microbial biosynthetic potential, these approaches offer a viable pathway toward replenishing the dwindling pipeline of novel therapeutics.

Despite these advances, important challenges persist. Computational predictions are inherently limited by existing databases and training sets, potentially biasing discovery toward known biosynthetic classes (Weber & Kim, 2016). Additionally, many activation strategies remain labor-intensive and strain-specific, limiting scalability. The heterogeneity observed across studies in this review reflects both biological complexity and methodological fragmentation, underscoring the need for more standardized, high-throughput activation and screening pipelines.

In conclusion, the findings of this systematic review support a unifying model in which microbial secondary metabolite discovery is most effective when genomics, activation strategies, and metabolomics are applied in concert. The consistent statistical advantages observed for integrated approaches validate the conceptual shift away from purely culture-based screening toward data-driven, systems-level discovery. As bioinformatics tools mature and experimental platforms become more scalable, the systematic exploration of microbial BGCs is poised to play a central role in addressing urgent biomedical and biotechnological challenges.

5. Limitations

Despite the growing sophistication of omics-driven discovery pipelines, several limitations continue to affect the interpretation and translational value of current findings. A major concern involves methodological heterogeneity across studies, including variations in sequencing platforms, genome mining algorithms, activation conditions, metabolomic workflows, and bioactivity assays, which complicates direct comparison and quantitative synthesis. Many investigations also rely on small experimental datasets or strain-specific observations, reducing broader ecological and clinical generalizability. In addition, computational prediction tools remain dependent on existing biosynthetic databases, potentially biasing annotations toward previously characterized gene cluster families while overlooking truly novel chemistry. Another challenge lies in the persistent gap between predicted biosynthetic potential and experimentally verified metabolite production, as many identified BGCs remain transcriptionally silent or poorly expressed under laboratory conditions. Publication bias may further skew interpretations toward positive findings. Collectively, these limitations emphasize the need for standardized methodologies, larger comparative datasets, and stronger experimental validation frameworks.

6. Conclusion

This review highlights how genome mining, biosynthetic gene cluster activation, and multi-omics integration are reshaping microbial natural product discovery. Rather than relying solely on conventional cultivation-based screening, contemporary approaches increasingly combine computational prediction, metabolomics, and targeted activation strategies to uncover previously inaccessible secondary metabolites. The evidence synthesized here suggests that integrated workflows substantially improve the likelihood of identifying biologically active compounds with antibacterial and antitumor relevance. Nevertheless, important technical and methodological challenges remain, particularly regarding scalability, standardization, and experimental validation. Continued refinement of bioinformatic tools and activation platforms will likely play a critical role in translating microbial genomic potential into clinically useful therapeutics.

References